New psoriasis drug shows promise in large trial

NCT ID NCT05975268

Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tested a new drug called JS005 in 747 adults with moderate-to-severe plaque psoriasis. JS005 is an antibody that blocks IL-17A, a protein that drives inflammation in psoriasis. The study compared JS005 to a placebo to see if it could improve skin clearance, measured by at least a 90% reduction in the Psoriasis Area and Severity Index (PASI 90) and a clear or almost clear skin assessment (sPGA 0/1) at 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: JS005 (an antibody that blocks IL-17A, a protein involved in inflammation)
What this could lead to: If successful, JS005 could offer a new treatment option for people with moderate-to-severe plaque psoriasis, helping clear skin and reduce symptoms.
What could go wrong: This is a single Phase 3 trial; results need replication. As with other biologics, risks include infections and allergic reactions. Long-term safety is not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

747 people

The number who actually took part.

Started

Aug 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects voluntarily particpate in this clinical study and sign the informed consent form. 2. Male and female patients aged 18-75 years at the time of screening (both inclusive). 3. Fertile female subjects must be willing to use a highly effective contraceptive method during the study period and 20 weeks (expected 5 half-lives) after the last study drug administration and have a negative pregnancy test during the screening period and prior to randomization. Exclusion Criteria: 1. Pregnant and lactating women. 2. A history of inflammatory bowel disease or other conditions with a high risk of perforation (e.g., severe gastrointestinal ulcers, etc.) or with other active autoimmune diseases (e.g., systemic lupus erythematosus, Sarcoidosis, etc.). 3. Have a type of psoriasis other than chronic plaque psoriasis (e.g., pustular, erythrodermic, and guttate psoriasis), drug-induced psoriasis, or have an active inflammatory skin disease other than psoriasis 4. Use of phototherapy, including but not limited to ultraviolet A phototherapy (with or without psoralens), ultraviolet B phototherapy, or excimer laser within 4 weeks prior to randomization. Subjects are unwilling to avoid excessive sunlight exposure within 4 weeks prior to randomization and during the study period; 5. A (current) history of systemic infection or serious infection requiring hospitalization and/or intravenous anti-infective therapy (e.g., antibiotics, antifungal agents, antiviral agents) within 12 weeks prior to randomization; a history of any active infection, other than common upper respiratory infections, within 2 weeks prior to randomization;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate-to-severe chronic plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate-to-severe chronic plaque psoriasis

Contacts and locations

Locations

Affiliated Hospital of Jiangsu University

Zhenjiang, Jiangsu, 212000, China
Baotou Central Hospital

Baotou, Neimenggu, 014040, China
Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, 100044, China
Beijing LuHe Hospital Capital Medical University

Beijing, Beijing Municipality, 101199, China
Beijing Tongren Hospital Affiliated to Capital Medical University

Beijing, Beijing Municipality, 100044, China
Beijing Tsinghua Changgung Hospital

Beijing, Beijing Municipality, 102218, China
Bethune First Hospital of Jilin University

Changchun, Jilin, 130021, China
Chengdu Second People's Hospital

Chengdu, Sichuan, 610017, China
China-Japan Friendship Hospital

Beijing, Beijing Municipality, 100044, China
Dermatology Hospital of Southern Medical University

Guangzhou, Guangdong, 510091, China
Dongguan People's Hospital

Dongguan, Guangdong, 523018, China
Guangdong General Hospital

Guangzhou, Guangdong, 510080, China
Guangzhou First People's Hospital

Guangzhou, Guangdong, 510180, China
Hangzhou First People's Hospital

Hangzhou, Zhejiang, 310006, China
Hangzhou Third People's Hospital

Hangzhou, Zhejiang, 310002, China
Inner Mongolia Baotou Steel Hospital

Baotou, Neimengu, 010000, China
Jiangxi Dermatology Hospital

Nanchang, Jiangxi, 330000, China
Jinan Central Hospital

Jinan, Shandong, 250013, China
Jingzhou Central Hospital

Jingzhou, Hubei, 434020, China
Lanzhou University Second Hospital

Lanzhou, Gansu, 730030, China
Lianyungang First People's Hospital

Lianyungang, Jiangsu, 222002, China
Medicine School of Xi'an Jiaotong University

Xian, Shanxi, 710004, China
Nanyang city first People's Hospital

Nanyang, Henan, 473000, China
Ningbo Huamei Hospital, University of Chinese Academy of Sciences

Beijing, Beijing Municipality, 100864, China
Ningxia Medical University General Hospital

Yinchuan, Ningxia, 750004, China
North East Central International Hospital Limited

Shenyang, Liaoning, China
Panjin Liao oil precious stone flower hospital

Panjin, Liaoning, 124011, China
Peking University People's Hospital

Beijing, Beijing Municipality, 100044, China
Peking University Third Hospital

Beijing, Beijing Municipality, 100044, China
Run Run Shaw Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310016, China
Shandong Dermatology Hospital

Jinan, Shandong, 250000, China
Shanghai Dermatology Hospital

Shanghai, Shanghai Municipality, 200050, China
Shengjing Hospital affiliated to China Medical University

Shenyang, Liaoning, 110004, China
Shenyang Hospital of Integrated Chinese and Western Medicine

Shenyang, Liaoning, 110021, China
Shenzhen People's Hospital

Shenzhen, Guangdong, 518020, China
Shiyan City People's Hospital

Shiyan, Hubei, 442000, China
Suining Central Hospital

Suining, Sichuan, 629000, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, 518107, China
The Affiliated Hospital of Chengde Medical College

Chengde, Hebei, China
The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, 233004, China
The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400016, China
The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, 350005, China
The First Affiliated Hospital of Gannan Medical College

Ganzhou, Jiangxi, 341000, China
The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215123, China
The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, 325000, China
The First Affiliated Hospital of Xi 'an Jiaotong University City:Xian

Xi’an, Shanxi, 710061, China
The First Affiliated Hospital of Xinxiang Medical College

Xinxiang, Henan, 453100, China
The First Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050000, China
The First Hospital of Jiaxing

Jiaxing, Zhejiang, 314001, China
The Second Affiliated Hospital of Anhui Medical University

Hefei, Anhui, 230601, China
The Second Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, 650118, China
The Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330006, China
The Second Affiliated Hospital of Xiamen Medical College

Xiamen, Fujian, 361023, China
The Second Hospital of Shanxi Medical University City:Taiyuan

Taiyuan, Shanxi, 030001, China
The Second Xiangya Hospital, Central South University

Changsha, Hunan, 410008, China
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

Tianjin, Tianjin Municipality, 300120, China
West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China
Wuhan University People's Hospital

Wuhan, Hubei, 430060, China
Wuxi Second People's Hospital

Wuxi, Jiangsu, 214002, China
Xiangya Third Hospital, Central South University

Changsha, Hunan, 410013, China
Xingtai People's Hospital

Xingtai, Hebei, 054031, China
Yancheng First People's Hospital

Yancheng, Jiangsu, 224006, China
Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, 310014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.